Latest Industry Insights

This article looks at the technologies currently being developed that can help to identify patients with a higher risk of prostate cancer, ultimately reducing the number of unnecessary biopsies.

Andrew Schulman explores why we need allogeneic therapies, the importance of collaboration to keep the momentum, and challenges and predictions for the future.

With growing sustainability demands, companies are looking for ways to demonstrate their green credentials. We spoke to Dr. Michael Frank to find out what ACT accreditation means for a company and why he thinks schemes like this are so important.

This article discusses how the culture of canine-derived organoid lines can be used to make meaningful observations in the emerging field of comparative oncology, prompting the next revolution in animal and human cancer studies.

HPLC system manufacturers have been striving to improve usability, accessibility and help users improve their experimental outcomes. And what better way to do that than to involve the users themselves in that development process.

We spoke with Bio-Rad’s Justin Barker to discover some of the challenges associated with gene expression analysis in oncology and learn about technology developments in this field.

We spoke to Prof. Oscar Ces, head of the Department of Chemistry at Imperial College London (ICL), to find out about the evolution of ICL’s White City Campus, the Agilent Measurement Suite and what it means for scientists across the board.

This article discusses the methodology of using common archived biospecimens for RNA sequencing in oncology applications, such as tumor profiling, introducing challenges and innovative solutions.

Hans van der Voorn tells us about some of the recent progress in the extracellular vesicle-based diagnostics and therapeutics landscape, particularly the need for industrial-scale EV isolation workflows.

Cutting-edge mass spectrometry proteomics technologies are accelerating the discovery and validation of novel targets in cancer, opening up new avenues for next-generation cancer therapeutics.